Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily,
highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of
extended-release niacin and 20 mg of laropiprant (ERN/LRPT) offers improved tolerability,
supporting a simplified 1-2 g dosing paradigm and improved adherence. Statins and niacin
improve endothelial function in cardiac patients, however, there is no data yet regarding the
additive effects of raising HDL-C by ERN/LRPT and statins on endothelial function in cardiac
patients. Thus the aim of the present study is to evaluate the impact of 3 months'
administration of ERN/LRPT compared to placebo added to statins on endothelial function,
assessed by brachial artery vasoreactivity in stable cardiac patients.